XenoPort up on arbaclofen placarbil plans

XenoPort Inc. (NASDAQ:XNPT) gained $1.35 (22%) to $7.55 on Monday after announcing plans to start Phase III testing in 1H11 for arbaclofen placarbil ( XP19986) to treat spasticity in multiple sclerosi...